Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 6/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709375 | 0.89 | ALDH1A1 (0.73) | ALDH1A1CYP3A4IDH1MIFTDP1 | |
| SCHEMBL1992145 | 0.86 | CYP4F2 (0.53) | ALDH1A1CYP4F2CYP4A11ACMSDTDP1 | |
| SCHEMBL22678650 | 0.86 | ALDH1A1 (0.70) | ALDH1A1CYP3A4IDH1TDP1 | |
| SCHEMBL1560391 | 0.86 | CYP4F2 (0.53) | ALDH1A1CYP4F2CYP4A11ACMSDTDP1 | |
| SCHEMBL6696949 | 0.86 | ALDH1A1 (0.59) | ALDH1A1CYP4F2CYP4A11CYP3A4IDH1 | |
| SCHEMBL7671543 | 0.86 | ALDH1A1 (0.63) | ALDH1A1CYP4F2CYP4A11CYP3A4IDH1 | |
| SCHEMBL5437580 | 0.85 | ALDH1A1 (0.58) | ALDH1A1CYP3A4IDH1MIFTDP1 | |
| SCHEMBL801397 | 0.82 | ALDH1A1 (0.63) | ALDH1A1CYP3A4IDH1MIFPRKDC | |
| SCHEMBL7671540 | 0.82 | ALDH1A1 (0.63) | ALDH1A1CYP3A4IDH1MIFPRKDC | |
| SCHEMBL16154053 | 0.82 | ALDH1A1 (0.63) | ALDH1A1CYP3A4IDH1MIFTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135490-A1 | Phenetanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1675821-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005044787-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135490-A1 | Phenetanolamine derivatives | ADRB2, ADRB1, ADRB3 | ALDH1A1 1056/4885CYP4F2 278/4885CYP4A11 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.